Patents by Inventor Sebastian Bernales

Sebastian Bernales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ATF6 INHIBITORS AND USES THEREOF
    Publication number: 20240124434
    Abstract: Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: May 26, 2023
    Publication date: April 18, 2024
    Inventors: Jennifer ALFARO, Sebastian BELMAR, Gonzalo Esteban NÚÑEZ VASQUEZ, Brahmam PUJALA, Balaji Dashrath SATHE, Pooja THAKRAL, Rajesh Kumar PATIDAR, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • Inhibitors of fibroblast activation protein
    Patent number: 11780821
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: October 10, 2023
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Jennifer Alfaro, Sebastian Belmar, Sebastian Bernales, Brahmam Pujala, Dayanand Panpatil, Bhawana Bhatt
  • INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20230144841
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Application
    Filed: September 14, 2022
    Publication date: May 11, 2023
    Inventors: Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sebastian BELMAR, Gonzalo Andrés URETA DÍAZ
  • GCN2 MODULATOR COMPOUNDS
    Publication number: 20230143059
    Abstract: The disclosures herein relate to novel compounds of Formula (1): or a salt thereof, wherein X, Y, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with General Control Nondepressible 2 (GCN2).
    Type: Application
    Filed: February 17, 2021
    Publication date: May 11, 2023
    Inventors: Balaji Dashrath SATHE, Brahmam PUJALA, Gonzalo Andrés URETA DÌAZ, Sebastian BERNALES, Jennifer BORTHWICK
  • MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20230083885
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: April 1, 2022
    Publication date: March 16, 2023
    Inventors: Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20230047589
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: August 10, 2021
    Publication date: February 16, 2023
    Inventors: Sebastian BERNALES, Luz Marina DELGADO OYARZO, Gonzalo Esteban NÚÑEZ VASQUEZ, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Bhawana BHATT, Sarvajit CHAKRAVARTY
  • MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20230042881
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: June 3, 2022
    Publication date: February 9, 2023
    Inventors: Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • ATF6 MODULATORS AND USES THEREOF
    Publication number: 20230028584
    Abstract: Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: October 9, 2020
    Publication date: January 26, 2023
    Inventors: Brahmam PUJALA, Balaji Dashrath SATHE, Sebastian BERNALES, Gonzalo Andrés URETA DÍAZ, Sebastian BELMAR
  • ATF6 MODULATORS AND USES THEREOF
    Publication number: 20220389001
    Abstract: Compounds (I) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: October 9, 2020
    Publication date: December 8, 2022
    Inventors: Brahmam PUJALA, Balaji Dashrath SATHE, Pooja THAKRAL, Sebastian BERNALES, Gonzalo Andrés URETA DÍAZ, Sebastian BELMAR
  • Inhibitors of fibroblast activation protein
    Patent number: 11504364
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Grant
    Filed: December 21, 2019
    Date of Patent: November 22, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales, Sebastian Belmar, Gonzalo Andrés Ureta Díaz
  • ARYL HYDROCARBON RECEPTOR ACTIVATORS
    Publication number: 20220281824
    Abstract: Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.
    Type: Application
    Filed: July 30, 2020
    Publication date: September 8, 2022
    Applicant: Oregon State University
    Inventors: Siva Kumar Kolluri, Nancy I. Kerkvliet, Sebastian Bernales, Jit Chakravarty, Brahmam Pujala, Pasha Khan, Varun Kumar, Abhinandan Danodia, Gonzalo Ureta
  • Modulators of integrated stress response pathway
    Patent number: 11318133
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: May 3, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Luz Marina Delgado Oyarzo, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20220071966
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: August 10, 2021
    Publication date: March 10, 2022
    Inventors: Luz Marina DELGADO OYARZO, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • Inhibitors of integrated stress response pathway
    Patent number: 11230542
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: January 25, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Sebastian Bernales, Luz Marina Delgado Oyarzo, Gonzalo Esteban Núñez Vasquez, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Bhawana Bhatt, Sarvajit Chakravarty
  • INHIBITORS OF ARGINASE
    Publication number: 20220017541
    Abstract: Compounds and compositions as inhibitors of arginase are provided. They may find use as therapeutic agents for the treatment of diseases or conditions associated with expression or activity of arginase.
    Type: Application
    Filed: November 21, 2019
    Publication date: January 20, 2022
    Inventors: Sebastian BELMAR, Jennifer ALFARO, Gonzalo Esteban NÚÑEZ VASQUEZ, Sebastian BERNALES, Brahmam PUJALA, Dayanand PANPATIL, Pasha KHAN, Sarvajit CHAKRAVARTY, Gonzalo Andrés URETA DÍAZ
  • Inhibitors of integrated stress response pathway
    Patent number: 11166942
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: November 9, 2021
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Luz Marina Delgado Oyarzo, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales, Sarvajit Chakravarty
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20210317102
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: June 11, 2020
    Publication date: October 14, 2021
    Inventors: Luz Marina DELGADO OYARZO, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • ATF6 INHIBITORS AND USES THEREOF
    Publication number: 20210221803
    Abstract: Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: August 12, 2020
    Publication date: July 22, 2021
    Inventors: Jennifer ALFARO, Sebastian BELMAR, Gonzalo Esteban NÚÑEZ VASQUEZ, Brahmam PUJALA, Balaji Dashrath SATHE, Pooja THAKRAL, Rajesh Kumar PATIDAR, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20200390759
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: June 11, 2020
    Publication date: December 17, 2020
    Inventors: Luz Marina DELGADO OYARZO, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES
  • ATF6 inhibitors and uses thereof
    Patent number: 10829485
    Abstract: Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Grant
    Filed: April 6, 2019
    Date of Patent: November 10, 2020
    Assignee: BLACK BELT TX LTD
    Inventors: Jennifer Alfaro, Sebastian Belmar, Gonzalo Esteban Núñez Vasquez, Brahmam Pujala, Balaji Dashrath Sathe, Pooja Thakral, Rajesh Kumar Patidar, Sebastian Bernales, Sarvajit Chakravarty